EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes

GLP-1-Rezeptoragonisten-Therapie und kardiorenale Outcomes bei Patient:innen ≥ 80 Jahre mit Typ-2-Diabetes

Jui-Cheng Chen, Yu-Wei Fang, Ya-Fang Liu, Mon-Ting Chen, Ming-Hsien Tsai iD

Journal of the American Geriatrics Society · 2026-01 · 74 (1) · 96-106

DOI: 10.1111/jgs.70187 ↗

Auf einen Blick

Bei 80-Jährigen und Älteren mit Typ-2-Diabetes waren GLP-1-Rezeptoragonisten im Vergleich zu DPP4-Inhibitoren mit geringeren Risiken für kardiovaskuläre, renale und Gesamtmortalitäts-Outcomes verbunden.

Fragestellung

Wie wirksam sind GLP-1-Rezeptoragonisten im Vergleich zu DPP4-Inhibitoren bei Patient:innen ≥ 80 Jahre mit Typ-2-Diabetes?

Methode

Retrospektive Kohortenstudie mit New-User- und aktivem Komparator-Design; Daten aus TriNetX USA von Januar 2018 bis Dezember 2022; Propensity-Score-Matching und Cox-Regression.

Ergebnisse

Nach 1:1-Matching je 11.464 Patient:innen. Geringeres Risiko für MACE (HR 0,86; 95 %-KI 0,81–0,91), MKE (HR 0,86; 95 %-KI 0,82–0,91), Hospitalisierung (HR 0,91; 95 %-KI 0,84–0,97) und Gesamtmortalität (HR 0,82; 95 %-KI 0,77–0,88).

Schlussfolgerung der Autor:innen

GLP-1-Rezeptoragonisten könnten bei Patient:innen ab 80 Jahren mit Typ-2-Diabetes relevante kardiorenale und Überlebensvorteile bieten.

Kernaussagen

  • MACE unter GLP-1-RA seltener als unter DPP4i
  • Auch MKE, Hospitalisierung und Mortalität niedriger
  • Keine Unterschiede bei Herzinsuffizienz oder Frakturen

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 24.10.2025. Verfasst von Jui-Cheng Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Shin Kong Wu Huo-Shih Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shin Kong Wu Ho-Su Memorial Hospital.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however, their efficacy in individuals aged 80 years and older remains understudied. To evaluate the efficacy of GLP‐1 RAs compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) in patients aged ≥ 80 years with T2DM. Participant and Setting De‐identified records from the TriNetX United States database identified 284,417 patients aged ≥ 80 years with T2DM, including 12,032 new GLP‐1 RA users and 28,230 new DPP4i users, analyzed from January 2018 to December 2022.

Methods

This retrospective cohort study utilized a new‐user and active comparator design to evaluate clinical outcomes between GLP‐1 RA and DPP4i users during a follow‐up period of up to 5 years. Propensity score matching, incorporating all the baseline covariates, was used to minimize baseline differences. The Cox proportional hazards regression model was used to estimate hazard ratios (HRs) for clinical outcomes. Sensitivity analyses were performed to validate the findings.

Results

After 1:1 propensity score matching, 11,464 patients were included in each group. Both cohorts had a mean age of 81.6 years; 47.7% were female, and 67% were White. GLP‐1 RA users had significantly lower risks of major adverse cardiovascular events (HR: 0.86, 95% CI: 0.81–0.91), major adverse kidney events (HR: 0.86, 95% CI: 0.82–0.91), all‐cause hospitalization (HR: 0.91, 95% CI: 0.84–0.97), and all‐cause mortality (HR: 0.82, 95% CI: 0.77–0.88) compared with DPP4i users. No significant differences were observed between the groups in the rate of heart failure or bone fractures.

Conclusions

GLP‐1 RAs may offer substantial cardiorenal and survival benefits in patients aged 80 years and older with T2DM. These findings support the use of GLP‐1 RAs as a therapeutic option in this high‐risk, older population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsHumansAged, 80 and overFemaleMaleRetrospective StudiesTreatment OutcomePropensity ScoreCardiovascular DiseasesUnited States

Stichwörter der Autor:innen

Type 2 diabetes mellituscardiovascular outcomesglucagon‐like peptide‐1 receptor agonistsolder adultsrenal outcomes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of General Medicine, Shin Kong Wu Huo-Shih Memorial Hospital, Taipei, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • Department of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
  • Data Analysis Group, Artificial Intelligence Research Center, Research Department, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
  • Department of Healthcare Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.

ORCID-Profile: Ming-Hsien Tsai

Förderung

  • Shin Kong Wu Ho-Su Memorial Hospital

Zitieren

APA

Chen, J. C., Fang, Y. W., Liu, Y. F., Chen, M. T., & Tsai, M. H. (2026). GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes. Journal of the American Geriatrics Society, 74(1), 96-106. https://doi.org/10.1111/jgs.70187

Vancouver

Chen JC, Fang YW, Liu YF, Chen MT, Tsai MH. GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes. Journal of the American Geriatrics Society. 2026;74(1):96-106. doi:10.1111/jgs.70187

BibTeX
@article{Chen2026,
  author = {Chen, Jui-Cheng and Fang, Yu-Wei and Liu, Ya-Fang and Chen, Mon-Ting and Tsai, Ming-Hsien},
  title = {GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes},
  journal = {Journal of the American Geriatrics Society},
  year = {2026},
  volume = {74},
  number = {1},
  pages = {96--106},
  doi = {10.1111/jgs.70187}
}
Kostenlos starten →